Trials / Completed
CompletedNCT02434029
Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis
Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to prove the superiority of a 6-weeks treatment with budesonide effervescent tablets versus placebo for the induction of clinico-pathological remission in patients with acute eosinophilic esophagitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide 1mg orodispersible tablet twice daily | |
| DRUG | Placebo orodispersible tablet twice daily |
Timeline
- Start date
- 2015-11-11
- Primary completion
- 2016-08-04
- Completion
- 2016-10-04
- First posted
- 2015-05-05
- Last updated
- 2017-02-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02434029. Inclusion in this directory is not an endorsement.